The US Food and Drug Administration (FDA) has granted final approval for the first generic naloxone hydrochloride nasal spray (Narcan, Teva Pharmaceuticals) that can stop or reverse the effects of an opioid overdose.

The FDA tentatively approved this generic drug product in June 2018.

Teva's generic naloxone nasal spray is the first for use in the community setting by individuals who have no medical training. The name-brand spray was approved in 2015.

The increased risk of cardiovascular disease (CVD) upon developing type 2 diabetes is similar in men and women, show data from a large UK-based study of newly diagnosed patients.

The new findings contradict prior studies and are the first to show that the proportionate CVD risk increase upon developing type 2 diabetes is similar between the sexes, with a nonsignificant relative risk ratio of 1.07.

However, women are still prescribed fewer therapies than men — including statins and angiotensin-converting-enzyme (ACE) inhibitors — raising concerns that women continue to receive suboptimal disease management.